An E-platform for Learners

Year: 2025

AstraZeneca Strikes Landmark Deal with Trump Administration Cuts U.S. Drug Prices, Commits $50 Billion to Domestic Manufacturing

AstraZeneca Strikes Landmark Deal with Trump Administration Cuts U.S. Drug Prices, Commits $50 Billion to Domestic Manufacturing

Pharm'Up

AstraZeneca has announced a landmark agreement with President Donald J. Trump’s administration aimed at significantly reducing prescription...

Ateneo Scientists Pioneer Immunoinformatics Research Towards a Potential Anti-Ulcer (H. pylori) Vaccine

Ateneo Scientists Pioneer Immunoinformatics Research Towards a Potential Anti-Ulcer (H. pylori) Vaccine

Pharm'Up

For centuries, painful stomach ulcers were mistakenly attributed to spicy foods or poor diet. However, modern research...

Precision Oncology Breakthrough: New Models and Molecular Markers Guide Liver Cancer Surgery

Precision Oncology Breakthrough: New Models and Molecular Markers Guide Liver Cancer Surgery

Pharm'Up

Liver cancer remains a highly lethal malignancy, with recurrence after surgery being a primary obstacle to long-term...

Lilly’s Oral GLP-1, Orforglipron, Achieves Superior Glycemic Control and Weight Loss in Head-to-Head Phase 3 Trials

Lilly’s Oral GLP-1, Orforglipron, Achieves Superior Glycemic Control and Weight Loss in Head-to-Head Phase 3 Trials

Pharm'Up

Eli Lilly and Company announced positive topline results from two pivotal Phase 3 trials, ACHIEVE-2 and ACHIEVE-5,...

Eli Lilly Partners with Cipla to Launch Second Brand of Tirzepatide (Yurpeak®) for Diabetes and Obesity in India

Eli Lilly Partners with Cipla to Launch Second Brand of Tirzepatide (Yurpeak®) for Diabetes and Obesity in India

Pharm'Up

Eli Lilly and Cipla Limited announced a commercial agreement to distribute and promote tirzepatide in India under...

Biocon Biologics Gains Health Canada Approval for Yesintek™ (Ustekinumab) Biosimilar to Treat Psoriasis and Autoimmune Conditions

Biocon Biologics Gains Health Canada Approval for Yesintek™ (Ustekinumab) Biosimilar to Treat Psoriasis and Autoimmune Conditions

Pharm'Up

Biocon Biologics Ltd (BBL), a global biosimilars company, announced that it received a Notice of Compliance (NOC)...

Novartis to Acquire RNA Therapeutics Innovator Avidity Biosciences for $12 Billion to Bolster Neuroscience and Muscle Disease Pipeline

Novartis to Acquire RNA Therapeutics Innovator Avidity Biosciences for $12 Billion to Bolster Neuroscience and Muscle Disease Pipeline

Pharm'Up

Novartis announced a definitive agreement to acquire Avidity Biosciences, Inc. (Nasdaq: RNA), a San Diego-based biopharmaceutical company...

USFDA Approves GSK’s Blenrep for Relapsed/Refractory Multiple Myeloma, Showing Superiority Over Daratumumab-based Regimen

USFDA Approves GSK’s Blenrep for Relapsed/Refractory Multiple Myeloma, Showing Superiority Over Daratumumab-based Regimen

Pharm'Up

GSK plc has announced that the US Food and Drug Administration (FDA) has granted approval for Blenrep...

Dr. Reddy’s to Launch Affordable Generic Version of Wegovy (Semaglutide) in 87 Countries

Dr. Reddy’s to Launch Affordable Generic Version of Wegovy (Semaglutide) in 87 Countries

Pharm'Up

Dr. Reddy’s Laboratories Ltd., a leading Indian pharmaceutical firm, is preparing a significant global market entry with...

Mazdutide, a Dual GLP-1/GCG Agonist, Demonstrates Superiority Over Semaglutide in Glycemic Control and Weight Loss for Type 2 Diabetes Patients

Mazdutide, a Dual GLP-1/GCG Agonist, Demonstrates Superiority Over Semaglutide in Glycemic Control and Weight Loss for Type 2 Diabetes Patients

Pharm'Up

Innovent Biologics announced that its fourth Phase 3 clinical trial, DREAMS-3, evaluating the novel drug mazdutide in...